Today: 30 January 2026
Subscribe
Browse Category

NASDAQ:OTLK News 30 December 2025 - 1 January 2026

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

NEW YORK, January 1, 2026, 04:59 ET — Market closed Outlook Therapeutics, Inc. (Nasdaq: OTLK) shares fell sharply in after-hours trading on Dec. 31 after the U.S. Food and Drug Administration again declined to approve its ONS-5010/LYTENAVA (bevacizumab-vikg) filing for wet age-related macular degeneration. The stock closed down 15.51% at $1.58 and slid to $0.58 after hours. Nasdaq The decision…
1 January 2026
····
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

NEW YORK, December 30, 2025, 01:25 ET — Market closed Outlook Therapeutics, Inc. shares closed Monday up 8.8% at $1.98 after trading between $1.78 and $1.98. The stock was last up about 2% at $2.02 in late after-hours trading, with about 5.7 million shares changing hands. StockAnalysis Traders are zeroed in on a Dec. 31 deadline at the U.S. Food…
30 December 2025
·····

Stock Market Today

  • Oversold Cocoa Futures Spark Technical Short Covering Amid Surplus Outlook
    January 30, 2026, 2:13 PM EST. March ICE NY cocoa futures rose 0.50% and London cocoa futures gained 0.75%, reversing a month-long decline that hit multi-year lows. Prices neared extreme oversold conditions, prompting technical short covering by funds. Global cocoa supplies remain ample, with StoneX forecasting a surplus of 287,000 MT for 2025/26 and 267,000 MT for 2026/27. Demand is weak; Barry Callebaut reported a 22% sales volume drop in cocoa, while European and Asian cocoa grindings fell sharply in Q4. Favorable West African growing conditions are boosting crop expectations, but producers are holding back shipments amid low prices. Ivory Coast cocoa exports are down 3.2% year-on-year, yet U.S. port inventories have rebounded, exerting further pressure on prices.
Go toTop